Insulet Net Income
| PODD Stock | USD 250.85 1.56 0.62% |
As of the 12th of February 2026, Insulet retains the Standard Deviation of 2.24, risk adjusted performance of (0.12), and Market Risk Adjusted Performance of (0.42). Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of Insulet, as well as the relationship between them. Please check out Insulet information ratio, and the relationship between the coefficient of variation and value at risk to decide if Insulet is priced fairly, providing market reflects its last-minute price of 250.85 per share. Given that Insulet has information ratio of (0.21), we strongly advise you to confirm Insulet's regular market performance to make sure the company can sustain itself at a future point.
Insulet Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.1431 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 481 M | 505.1 M | |
| Net Income From Continuing Ops | 481 M | 505.1 M | |
| Net Income Applicable To Common Shares | 5.3 M | 5.6 M | |
| Net Income Per Share | 5.37 | 5.64 | |
| Net Income Per E B T | 1.60 | 1.05 |
Insulet | Net Income | Build AI portfolio with Insulet Stock |
Analyzing Insulet's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Insulet's current valuation and future prospects.
Latest Insulet's Net Income Growth Pattern
Below is the plot of the Net Income of Insulet over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Insulet financial statement analysis. It represents the amount of money remaining after all of Insulet operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Insulet's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Insulet's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 418.3 M | 10 Years Trend |
|
Net Income |
| Timeline |
Insulet Net Income Regression Statistics
| Arithmetic Mean | 76,853,721 | |
| Geometric Mean | 40,442,111 | |
| Coefficient Of Variation | 256.53 | |
| Mean Deviation | 153,332,631 | |
| Median | 3,292,000 | |
| Standard Deviation | 197,151,209 | |
| Sample Variance | 38868.6T | |
| Range | 578.6M | |
| R-Value | 0.79 | |
| Mean Square Error | 15553.9T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | 30,861,382 | |
| Total Sum of Squares | 621897.6T |
Insulet Net Income History
Other Fundumenentals of Insulet
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Insulet Net Income component correlations
Insulet Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Insulet is extremely important. It helps to project a fair market value of Insulet Stock properly, considering its historical fundamentals such as Net Income. Since Insulet's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Insulet's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Insulet's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Insulet diversify its offerings? Factors like these will boost the valuation of Insulet. Anticipated expansion of Insulet directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Insulet data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.148 | Earnings Share 3.41 | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets |
Understanding Insulet requires distinguishing between market price and book value, where the latter reflects Insulet's accounting equity. The concept of intrinsic value - what Insulet's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Insulet's price substantially above or below its fundamental value.
It's important to distinguish between Insulet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Insulet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Insulet's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Insulet 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Insulet's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Insulet.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Insulet on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Insulet or generate 0.0% return on investment in Insulet over 90 days. Insulet is related to or competes with DexCom, STERIS Plc, Koninklijke Philips, Zimmer Biomet, Biogen, Laboratory, and Waters. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabete... More
Insulet Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Insulet's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Insulet upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 13.53 | |||
| Value At Risk | (3.62) | |||
| Potential Upside | 3.24 |
Insulet Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Insulet's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Insulet's standard deviation. In reality, there are many statistical measures that can use Insulet historical prices to predict the future Insulet's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.43) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Insulet's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Insulet February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 1.55 | |||
| Coefficient Of Variation | (625.34) | |||
| Standard Deviation | 2.24 | |||
| Variance | 5.04 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.45) | |||
| Total Risk Alpha | (0.63) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 13.53 | |||
| Value At Risk | (3.62) | |||
| Potential Upside | 3.24 | |||
| Skewness | (0.73) | |||
| Kurtosis | 4.18 |
Insulet Backtested Returns
Insulet holds Efficiency (Sharpe) Ratio of -0.19, which attests that the entity had a -0.19 % return per unit of risk over the last 3 months. Insulet exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Insulet's Standard Deviation of 2.24, market risk adjusted performance of (0.42), and Risk Adjusted Performance of (0.12) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.86, which attests to possible diversification benefits within a given portfolio. Insulet returns are very sensitive to returns on the market. As the market goes up or down, Insulet is expected to follow. At this point, Insulet has a negative expected return of -0.44%. Please make sure to check out Insulet's skewness, as well as the relationship between the daily balance of power and day typical price , to decide if Insulet performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.81 |
Very good predictability
Insulet has very good predictability. Overlapping area represents the amount of predictability between Insulet time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Insulet price movement. The serial correlation of 0.81 indicates that around 81.0% of current Insulet price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.81 | |
| Spearman Rank Test | 0.87 | |
| Residual Average | 0.0 | |
| Price Variance | 285.2 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Insulet Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Insulet reported net income of 418.3 M. This is 22.57% higher than that of the Health Care Equipment & Supplies sector and 75.67% higher than that of the Health Care industry. The net income for all United States stocks is 26.74% higher than that of the company.
Insulet Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insulet's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insulet could also be used in its relative valuation, which is a method of valuing Insulet by comparing valuation metrics of similar companies.Insulet is currently under evaluation in net income category among its peers.
Insulet ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Insulet's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Insulet's managers, analysts, and investors.Environmental | Governance | Social |
Insulet Institutional Holders
Institutional Holdings refers to the ownership stake in Insulet that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Insulet's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Insulet's value.| Shares | Fidelity International Ltd | 2025-06-30 | 1.1 M | Norges Bank | 2025-06-30 | 1 M | Goldman Sachs Group Inc | 2025-06-30 | 988.9 K | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 832.5 K | Citadel Advisors Llc | 2025-06-30 | 771.5 K | Federated Hermes Inc | 2025-06-30 | 723.4 K | Northern Trust Corp | 2025-06-30 | 705.6 K | Charles Schwab Investment Management Inc | 2025-06-30 | 681.1 K | Artisan Partners Limited Partnership | 2025-06-30 | 671.5 K | Vanguard Group Inc | 2025-06-30 | 8.7 M | Fmr Inc | 2025-06-30 | 7.5 M |
Insulet Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0874 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 18.01 B | ||||
| Shares Outstanding | 70.35 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 99.72 % | ||||
| Number Of Shares Shorted | 1.93 M | ||||
| Price To Book | 12.83 X | ||||
| Price To Sales | 7.00 X | ||||
| Revenue | 2.07 B | ||||
| Gross Profit | 1.79 B | ||||
| EBITDA | 423.7 M | ||||
| Net Income | 418.3 M | ||||
| Cash And Equivalents | 708.6 M | ||||
| Cash Per Share | 10.21 X | ||||
| Total Debt | 1.42 B | ||||
| Debt To Equity | 3.34 % | ||||
| Current Ratio | 4.69 X | ||||
| Book Value Per Share | 19.68 X | ||||
| Cash Flow From Operations | 430.3 M | ||||
| Short Ratio | 2.24 X | ||||
| Earnings Per Share | 3.41 X | ||||
| Price To Earnings To Growth | 1.92 X | ||||
| Target Price | 369.64 | ||||
| Number Of Employees | 3.9 K | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 17.66 B | ||||
| Total Asset | 3.09 B | ||||
| Retained Earnings | 40.3 M | ||||
| Working Capital | 1.36 B | ||||
| Current Asset | 190.76 M | ||||
| Current Liabilities | 65.16 M | ||||
| Net Asset | 3.09 B |
About Insulet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insulet's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insulet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insulet based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Will Health Care Equipment & Supplies sector continue expanding? Could Insulet diversify its offerings? Factors like these will boost the valuation of Insulet. Anticipated expansion of Insulet directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Insulet data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.148 | Earnings Share 3.41 | Revenue Per Share | Quarterly Revenue Growth 0.299 | Return On Assets |
Understanding Insulet requires distinguishing between market price and book value, where the latter reflects Insulet's accounting equity. The concept of intrinsic value - what Insulet's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Insulet's price substantially above or below its fundamental value.
It's important to distinguish between Insulet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Insulet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Insulet's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.